Aquestive Therapeutics (AQST) Given New $30.00 Price Target at Wedbush
Aquestive Therapeutics (NASDAQ:AQST) had its target price lifted by research analysts at Wedbush from $29.00 to $30.00 in a research note issued on Thursday. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 263.64% from the company’s previous close.
Several other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Royal Bank of Canada set a $24.00 price objective on shares of Aquestive Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 7th. JMP Securities began coverage on shares of Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating and a $29.00 price objective on the stock. Finally, BMO Capital Markets began coverage on shares of Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Aquestive Therapeutics currently has an average rating of “Buy” and a consensus target price of $27.67.
Shares of AQST stock opened at $8.25 on Thursday. Aquestive Therapeutics has a one year low of $7.47 and a one year high of $20.70. The company has a current ratio of 3.63, a quick ratio of 3.42 and a debt-to-equity ratio of 1.88.
In related news, CEO Keith J. Kendall purchased 7,950 shares of the company’s stock in a transaction dated Friday, November 23rd. The shares were purchased at an average price of $10.10 per share, with a total value of $80,295.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO John T. Maxwell purchased 10,000 shares of the company’s stock in a transaction dated Wednesday, November 21st. The shares were bought at an average cost of $9.80 per share, for a total transaction of $98,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 25,650 shares of company stock worth $249,931.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Keybank National Association OH purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $239,000. Point72 Asset Management L.P. purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $350,000. Citadel Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $451,000. Engineers Gate Manager LP purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $464,000. Finally, Brant Point Investment Management LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $622,000. 64.49% of the stock is currently owned by hedge funds and other institutional investors.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.